

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-5. (Canceled)

6. (Currently Amended) A method for ~~detecting the presence of lymphoma in a patient~~ determining whether a patient has lymphoma, comprising the steps of:

- (a) obtaining a lymphoid sample from a patient suspected of having lymphoma;
- (b) contacting the ~~biological lymphoid sample~~ with a ~~binding agent~~ an antibody or antigen-binding fragment thereof that binds to the polypeptide of SEQ ID NO:9611;
- (c) detecting in the lymphoid sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the ~~binding agent antibody or antigen-binding fragment thereof~~; and
- (d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control sample comprising lymphoid tissue from a subject without lymphoma, wherein an amount of polypeptide detected in step (c) that is greater than the amount of polypeptide in the control sample ~~is indicative of the presence of lymphoma in the patient~~ indicates that the patient has lymphoma.

7.-27. (Canceled)

28. (Currently Amended) The method of claim 6, wherein the ~~binding agent antibody or antigen-binding fragment thereof~~ is a monoclonal antibody.

29. (Currently Amended) A method for ~~detecting the presence of lymphoma in a patient~~ determining whether a patient has lymphoma, comprising the steps of:

- (a) obtaining a B-cell sample from a patient suspected of having lymphoma;

(b) contacting the ~~biological~~ B-cell sample with a ~~binding agent~~ an antibody or antigen-binding fragment thereof that binds to the polypeptide of SEQ ID NO:9611;

(c) detecting in the ~~B-cell~~ sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the ~~binding agent~~ antibody or antigen-binding fragment thereof; and

(d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control B-cell sample from a subject without lymphoma, wherein an amount of polypeptide detected in step (c) that is greater than the amount of polypeptide in the control sample ~~is indicative of the presence of lymphoma in the patient~~ indicates that the patient has lymphoma.

30. (Canceled)

31. (Currently Amended) The method of claim 29, wherein the ~~binding agent~~ antibody or antigen-binding fragment thereof is a monoclonal antibody.

32. (Currently Amended) A method for ~~detecting the presence of lymphoma in a patient~~ determining whether a patient has lymphoma, comprising the steps of:

(a) obtaining a lymph node sample from a patient suspected of having lymphoma;

(b) contacting the ~~biological~~ lymph node sample with a ~~binding agent~~ an antibody or antigen-binding fragment thereof that binds to the polypeptide of SEQ ID NO:9611;

(c) detecting in the ~~lymph node~~ sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the ~~binding agent~~ antibody or antigen-binding fragment thereof; and

(d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control lymph node sample from a subject without lymphoma, wherein an amount of polypeptide detected in step (c) that is greater than the amount of polypeptide in the control sample ~~is indicative of the presence of lymphoma in the patient~~ indicates that the patient has lymphoma.

33. (Canceled)

34. (Currently Amended) The method of claim 32, wherein the binding agent antibody or antigen-binding fragment thereof is a monoclonal antibody.